Is RLMD or AMLX more profitable?

Amylyx Pharmaceuticals' return on equity of -55.69% beat Relmada Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -71.22% -64.46% Amylyx Pharmaceuticals N/A -55.69% -50.73%

Does the media refer more to RLMD or AMLX?

In the previous week, Relmada Therapeutics had 4 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 10 mentions for Relmada Therapeutics and 6 mentions for Amylyx Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 1.29 beat Amylyx Pharmaceuticals' score of 0.95 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amylyx Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AGIO or RLMD?

In the previous week, Agios Pharmaceuticals had 20 more articles in the media than Relmada Therapeutics. MarketBeat recorded 30 mentions for Agios Pharmaceuticals and 10 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.29 beat Agios Pharmaceuticals' score of 0.41 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 8 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Relmada Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IOVA or RLMD?

In the previous week, Relmada Therapeutics had 2 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 10 mentions for Relmada Therapeutics and 8 mentions for Iovance Biotherapeutics. Relmada Therapeutics' average media sentiment score of 1.29 beat Iovance Biotherapeutics' score of 0.22 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RLMD or ZLAB?

In the previous week, Relmada Therapeutics had 5 more articles in the media than Zai Lab. MarketBeat recorded 10 mentions for Relmada Therapeutics and 5 mentions for Zai Lab. Relmada Therapeutics' average media sentiment score of 1.29 beat Zai Lab's score of 0.11 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zai Lab 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RLMD or HRMY?

In the previous week, Harmony Biosciences had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 11 mentions for Harmony Biosciences and 10 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.29 beat Harmony Biosciences' score of 0.99 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Relmada Therapeutics (RLMD) Competitors

$5.30 -0.01 (-0.19%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$5.28 -0.01 (-0.28%)

As of 08/3/2026 07:39 PM Eastern

Compare

RLMD vs. AMLX, AGIO, IOVA, ZLAB, and HRMY

Should you buy Relmada Therapeutics stock or one of its competitors? MarketBeat compares Relmada Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Relmada Therapeutics include Amylyx Pharmaceuticals (AMLX), Agios Pharmaceuticals (AGIO), Iovance Biotherapeutics (IOVA), Zai Lab (ZLAB), and Harmony Biosciences (HRMY).

How does Relmada Therapeutics compare to Amylyx Pharmaceuticals?

Relmada Therapeutics (NASDAQ:RLMD) and Amylyx Pharmaceuticals (NASDAQ:AMLX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

In the previous week, Relmada Therapeutics had 4 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 10 mentions for Relmada Therapeutics and 6 mentions for Amylyx Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 1.29 beat Amylyx Pharmaceuticals' score of 0.95 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amylyx Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relmada Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Amylyx Pharmaceuticals has a beta of -0.21, indicating that its share price is 121% less volatile than the broader market.

Amylyx Pharmaceuticals' return on equity of -55.69% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%

Relmada Therapeutics has higher earnings, but lower revenue than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Amylyx Pharmaceuticals	$87.37M	25.67	-$144.74M	-$1.50	N/A

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Amylyx Pharmaceuticals shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 10.9% of Amylyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Relmada Therapeutics currently has a consensus price target of $12.00, indicating a potential upside of 126.42%. Amylyx Pharmaceuticals has a consensus price target of $25.38, indicating a potential upside of 25.81%. Given Relmada Therapeutics' higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Summary

Relmada Therapeutics beats Amylyx Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Relmada Therapeutics compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Agios Pharmaceuticals presently has a consensus target price of $40.88, indicating a potential upside of 33.84%. Relmada Therapeutics has a consensus target price of $12.00, indicating a potential upside of 126.42%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Relmada Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Relmada Therapeutics	N/A	-71.22%	-64.46%

In the previous week, Agios Pharmaceuticals had 20 more articles in the media than Relmada Therapeutics. MarketBeat recorded 30 mentions for Agios Pharmaceuticals and 10 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.29 beat Agios Pharmaceuticals' score of 0.41 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	8 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Neutral
Relmada Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relmada Therapeutics has lower revenue, but higher earnings than Agios Pharmaceuticals. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	33.74	-$412.78M	-$7.01	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Agios Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

45.2% of Relmada Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Relmada Therapeutics beats Agios Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Relmada Therapeutics compare to Iovance Biotherapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

In the previous week, Relmada Therapeutics had 2 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 10 mentions for Relmada Therapeutics and 8 mentions for Iovance Biotherapeutics. Relmada Therapeutics' average media sentiment score of 1.29 beat Iovance Biotherapeutics' score of 0.22 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relmada Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	7.32	-$390.98M	-$0.95	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Iovance Biotherapeutics currently has a consensus price target of $8.43, indicating a potential upside of 95.11%. Relmada Therapeutics has a consensus price target of $12.00, indicating a potential upside of 126.42%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Iovance Biotherapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Relmada Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Summary

Relmada Therapeutics beats Iovance Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Relmada Therapeutics compare to Zai Lab?

Relmada Therapeutics (NASDAQ:RLMD) and Zai Lab (NASDAQ:ZLAB) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, media sentiment, institutional ownership and valuation.

Relmada Therapeutics has higher earnings, but lower revenue than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Zai Lab	$460.16M	4.50	-$175.54M	-$1.62	N/A

Relmada Therapeutics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, Zai Lab has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 41.7% of Zai Lab shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 4.9% of Zai Lab shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Relmada Therapeutics has a net margin of 0.00% compared to Zai Lab's net margin of -39.29%. Zai Lab's return on equity of -24.32% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Zai Lab	-39.29%	-24.32%	-15.52%

Relmada Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 126.42%. Zai Lab has a consensus price target of $40.00, indicating a potential upside of 120.02%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Relmada Therapeutics is more favorable than Zai Lab.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Zai Lab	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Relmada Therapeutics had 5 more articles in the media than Zai Lab. MarketBeat recorded 10 mentions for Relmada Therapeutics and 5 mentions for Zai Lab. Relmada Therapeutics' average media sentiment score of 1.29 beat Zai Lab's score of 0.11 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zai Lab	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Relmada Therapeutics beats Zai Lab on 11 of the 15 factors compared between the two stocks.

How does Relmada Therapeutics compare to Harmony Biosciences?

Relmada Therapeutics (NASDAQ:RLMD) and Harmony Biosciences (NASDAQ:HRMY) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Relmada Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 126.42%. Harmony Biosciences has a consensus target price of $42.63, suggesting a potential upside of 19.73%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Relmada Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Harmony Biosciences has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
Harmony Biosciences	$868.45M	2.37	$158.69M	$2.48	14.35

Harmony Biosciences has a net margin of 16.20% compared to Relmada Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Harmony Biosciences	16.20%	17.19%	11.99%

In the previous week, Harmony Biosciences had 1 more articles in the media than Relmada Therapeutics. MarketBeat recorded 11 mentions for Harmony Biosciences and 10 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.29 beat Harmony Biosciences' score of 0.99 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relmada Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

Summary

Harmony Biosciences beats Relmada Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Relmada Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RLMD vs. The Competition

Export

Metric	Relmada Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$556.97M	$11.61B	$6.86B	$12.44B
Dividend Yield	N/A	2.73%	2.60%	10.03%
P/E Ratio	-4.86	793.98	280.74	24.99
Price / Sales	N/A	731.95	588.16	90.43
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	4.49	10.39	11.02	6.21
Net Income	-$57.38M	$2.80B	$3.48B	$347.49M
7 Day Performance	1.34%	0.76%	0.81%	1.29%
1 Month Performance	-15.61%	-3.80%	-4.15%	-3.59%
1 Year Performance	761.79%	154.73%	61.47%	18.38%

Relmada Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RLMD Relmada Therapeutics	2.3268 of 5 stars	$5.30 -0.2%	$12.00 +126.4%	+797.7%	$556.97M	N/A	N/A	10	Positive News Upcoming Earnings
AMLX Amylyx Pharmaceuticals	4.0132 of 5 stars	$19.46 -0.2%	$24.63 +26.5%	+161.3%	$2.16B	$87.37M	N/A	200	News Coverage Upcoming Earnings Analyst Forecast
AGIO Agios Pharmaceuticals	2.7956 of 5 stars	$36.34 -1.7%	$42.78 +17.7%	-12.7%	$2.16B	$54.03M	N/A	390	Earnings Report Analyst Revision Gap Up
IOVA Iovance Biotherapeutics	2.5905 of 5 stars	$4.79 -2.3%	$8.43 +76.1%	+61.2%	$2.13B	$263.50M	N/A	500	Upcoming Earnings
ZLAB Zai Lab	3.1897 of 5 stars	$18.64 0.0%	$40.00 +114.6%	-50.6%	$2.12B	$460.16M	N/A	1,784	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RLMD) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Relmada Therapeutics (RLMD) Competitors

RLMD vs. AMLX, AGIO, IOVA, ZLAB, and HRMY

How does Relmada Therapeutics compare to Amylyx Pharmaceuticals?

Summary

How does Relmada Therapeutics compare to Agios Pharmaceuticals?

Summary

How does Relmada Therapeutics compare to Iovance Biotherapeutics?

Summary

How does Relmada Therapeutics compare to Zai Lab?

Summary

How does Relmada Therapeutics compare to Harmony Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Relmada Therapeutics (RLMD) Competitors

RLMD vs. AMLX, AGIO, IOVA, ZLAB, and HRMY

How does Relmada Therapeutics compare to Amylyx Pharmaceuticals?

Does the media refer more to RLMD or AMLX?

Which has more volatility & risk, RLMD or AMLX?

Is RLMD or AMLX more profitable?

Which has better earnings & valuation, RLMD or AMLX?

Do institutionals and insiders have more ownership in RLMD or AMLX?

Do analysts prefer RLMD or AMLX?

Summary

How does Relmada Therapeutics compare to Agios Pharmaceuticals?

Do analysts rate AGIO or RLMD?

Is AGIO or RLMD more profitable?

Does the media favor AGIO or RLMD?

Which has higher earnings and valuation, AGIO or RLMD?

Which has more risk & volatility, AGIO or RLMD?

Do institutionals and insiders believe in AGIO or RLMD?

Summary

How does Relmada Therapeutics compare to Iovance Biotherapeutics?

Does the media favor IOVA or RLMD?

Which has higher earnings & valuation, IOVA or RLMD?

Do analysts recommend IOVA or RLMD?

Do insiders and institutionals believe in IOVA or RLMD?

Which has more risk & volatility, IOVA or RLMD?

Is IOVA or RLMD more profitable?

Summary

How does Relmada Therapeutics compare to Zai Lab?

Which has higher valuation and earnings, RLMD or ZLAB?

Which has more risk and volatility, RLMD or ZLAB?

Do institutionals and insiders have more ownership in RLMD or ZLAB?

Is RLMD or ZLAB more profitable?

Do analysts prefer RLMD or ZLAB?

Does the media prefer RLMD or ZLAB?

Summary

How does Relmada Therapeutics compare to Harmony Biosciences?

Do insiders & institutionals hold more shares of RLMD or HRMY?

Do analysts rate RLMD or HRMY?

Which has preferable valuation & earnings, RLMD or HRMY?

Is RLMD or HRMY more profitable?

Does the media refer more to RLMD or HRMY?

Which has more risk and volatility, RLMD or HRMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RLMD vs. The Competition

Relmada Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools